Kamaptive Licence and Royalty Agreement with CMR Surgical

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has signed a non-exclusive Intellectual Property Licence and a Royalty Agreement with CMR Surgical Limited, the global surgical robotics business, to integrate certain aspects of Creo’s technology with the Versius® Surgical Robotic System, through Creo’s “Powered by Kamaptive” licensing programme. Licensing terms and commercial royalties have been agreed but will remain undisclosed.

CMR’s next-generation surgical robot, Versius®, is a significant new entrant into the robotic surgery space and is being used to perform both routine and complex laparoscopic procedures worldwide across a range of specialties including gynaecology, colorectal surgery, thoracic surgery, general surgery and urology.

Through Creo’s Kamaptive licensing programme, strategic partners are being carefully selected with whom Creo can licence and develop its technology for use in adjacent and complementary markets. The Agreements are the latest licensing deal under Creo’s Kamaptive licensing programme.

Craig Gulliford, Chief Executive Officer of Creo, commented:

We are delighted to announce our second robotics partnership through our Kamaptive programme with CMR Surgical. Versius® has been used for a wide range of laparoscopic procedures worldwide, and we look forward to collaborating with CMR to integrate Creo’s ground-breaking minimally invasive technology with the Versius® system, driven by a shared goal to improve outcomes for even more patients. Exploring the use of our technology in the fast-growing robotic surgery space with another prestigious partner provides further validation of our technology and its versatility.

About Kamaptive Technology

Creo has developed multi-modal adaptive technology to optimise surgical capability and patient outcomes under its “Powered by Kamaptive” brand. Kamaptive is a seamless, intuitive integration of energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions and lies at the heart of Creo’s CROMA Advance Energy platform and associated electrosurgical medical device technology.

Posted 10/24/22

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance


25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months


12 September 2023

Half Year Report: H1-2023


19 June 2023

Speedboat Inject cleared for upper GI use in Europe


01 June 2023

Speedboat™ Inject selected by NICE for assessment


23 May 2023

First in-human milestone reached for MicroBlate™ Flex as part of Lung Tissue ablation clinical study